Publications by authors named "R Bazaz"
Objective: Evidence for necrotising otitis externa (NOE) diagnosis and management is limited, and outcome reporting is heterogeneous. International best practice guidelines were used to develop consensus diagnostic criteria and a core outcome set (COS).
Methods: The study was pre-registered on the Core Outcome Measures in Effectiveness Trials (COMET) database.
Background: Aspergillus nodules are classified as a subset of chronic pulmonary aspergillosis. The optimal management approach is not known as their natural evolution following biopsy, the rate of progression to chronic cavitary pulmonary aspergillosis (CCPA) and the effect of antifungal treatment have not been described.
Objectives: To describe the clinical course of patients diagnosed with Aspergillus nodules and the effect of antifungal treatment.
Background: Implantable cardioverter-defibrillation (ICD) shocks after left ventricular assist device therapy (LVAD) are associated with adverse clinical outcomes. Little is known about the association of pre-LVAD ICD shocks on post-LVAD clinical outcomes and whether LVAD therapy affects the prevalence of ICD shocks.
Objectives: The purpose of this study was to determine whether pre-LVAD ICD shocks are associated with adverse clinical outcomes post-LVAD and to compare the prevalence of ICD shocks before and after LVAD therapy.
Article Synopsis
- This study investigates device-related thrombus (DRT) occurrences after left atrial appendage closure (LAAC), focusing on how often it persists or recurs.
- It found that about 29% of DRT cases persist, with being female and having a larger initial thrombus size being significant predictors.
- Unfavorable DRT evolution is linked to a higher rate of thromboembolic events, emphasizing the importance of monitoring thrombus size post-LAAC.
Article Synopsis
- - Allergic bronchopulmonary aspergillosis and invasive fungal diseases are serious health issues that lead to high rates of illness and death, but current inhaled antifungal treatments are not effective and can cause negative side effects.
- - The development of new inhaled antifungal therapies is complicated by issues like a lack of proper testing models, diverse patient backgrounds, and difficulty establishing clear clinical trial criteria and outcomes.
- - On September 25, 2020, the FDA held a workshop with experts to discuss ways to encourage the development of inhaled antifungal drugs, address the limitations of current research methods, and gather insights from patients and the industry.